This morning, Acadia Pharmaceuticals (ACAD) announced that it has entered into an agreement with Biovail Labs (BLS), a wholly owned subsidiary of Valeant Pharmaceuticals International, to conclude the previously established collaboration to develop and commercialize pimavanserin in the U.S. and Canada. Acadia has now reclaimed global rights to the drug. As part of the transaction, Biovail [...] (ACAD) Acadia Pharmaceuticals Gets Pimavanserin Back